Biopharmaceutical company PlasmaGen Biosciences has raised Rs 225 crore (roughly $27 million) in equity funding from UK-based investment management firm Artian Investments, Ashish Rameshchandra Kacholia and other high-net-worth individuals (HNIs). Kacholia is known to pick up stakes in companies and invest in public markets.

PlasmaGen BioSciences Private Limited is India’s first Plasma Protein Therapeutics focused company established in 2010 at Bengaluru. 

But what prompted us to become India’s first Plasma Protein Therapeutics focused company? Read on to know our story. 

Years ago, India was plagued with a rampant unawareness about plasma benefits which led to ~6 lakh liters of blood wastage every year. Such disheartening statistics strengthened our resolve to embark on creating awareness among blood banks as well in addition to the management of plasma and marketing of plasma products for India. 


Plasmagen Biosciences Raises Rs 225 Crore In Equity Funding

Description

Company Information

Related People

Plasmagen Biosciences Raises Rs 225 Crore In Equity Funding

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information